Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.45% to $662.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% ...

What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Two students from Good Hope Country Day School (GHCDS) have earned a prestigious opportunity to present their groundbreaking ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Trua Senior Living Locators ? a fast-growing national franchise that helps families find ideal senior living options for their loved ones ? recently launched in Raleigh North Carolina. This marks the ...

Commonwealth Equity Services LLC reduced its stake in Regeneron Pharmaceuticals by 5.1% in Q4, selling 967 shares and ...